MAP2K2 and melanoma: To evaluate how TGFβ signaling influences melanoma cells in absence or presence of MAPK pathway inhibition, we first tested human melanoma cell lines harboring either oncogenic NRASQ61X or BRAFV600E mutations for their sensitivity to trametinib, a selective MEK1/MEK2 inhibitor [32] referred later as MEKi.